Biocorrx Inc - SIC # 8361 - RESIDENTIAL CARE

Ticker Exchange SIC # Website Latest Ticker
BICX Over the counter 8361 https://www.biocorrx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biocorrx Inc

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia - Apr 3rd, 2024 12:30 pm
BioCorRx Reports Business Update for 2023 - Apr 2nd, 2024 12:30 pm
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD - Feb 28th, 2024 3:52 pm
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors - Feb 8th, 2024 2:58 pm
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President - Jan 9th, 2024 1:30 pm
BioCorRx Reports Business Update for the Third Quarter of 2023 - Nov 14th, 2023 5:52 pm
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder - Aug 15th, 2023 1:00 pm
BioCorRx Reports Business Update for the Second Quarter of 2023 - Aug 14th, 2023 8:34 pm
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder - Jul 18th, 2023 12:30 pm
BioCorRx Provides Business Update for the First Quarter of 2023 - May 16th, 2023 12:30 pm